Establishment of ultrasensitive PCR assay targeting cell-freeEBVDNA for early detection of nasopharyngeal carcinoma
Authors:   Biomedical & Pharmaceutical Applied Research Centre, Vietnam Military Medical University, Ho Huu Tho , Anh Vu Nguyen Quynh ,   Biomedical & Pharmaceutical Applied Research Centre, Vietnam Military Medical University, Do Tram Anh ,   ENT Department, 103 Hospital, Vietnam Military Medical University, Nguyen Dinh Ung ,   Biomedical & Pharmaceutical Applied Research Centre, Vietnam Military Medical University, Dinh Thi Thu Hang ,   Biomedical & Pharmaceutical Applied Research Centre, Vietnam Military Medical University, Bui Tien Sy ,   Department of Molecular Biology, 108 Military Central Hospital, Hoang Dao Chinh ,   Department of Oncology and Radiation, 108 Military Central Hospital, Le Minh Ky ,   Oncology and Head&Neck Surgery Centre, Vietnam National ENT Hospital, Vu Truong Phong ,   Oncology and Head&Neck Surgery Centre, Vietnam National ENT Hospital, Ngo Thanh Tung ,   Department of Head&Neck Cancer and Radiation Oncology, Vietnam National K Hospital, Nguyen Kim Luu ,   Department of Head&Neck Cancer and Radiation Oncology, Vietnam National K Hospital, Luu Truong Sinh ,   Biomedical & Pharmaceutical Applied Research Centre, Vietnam Military Medical University, Nguyen Van Ba ,   Oncology and Nuclear Medicine Centre, 103 Hospital, Vietnam Military Medical University, Ho Anh Son ,   Biomedical & Pharmaceutical Applied Research Centre, Vietnam Military Medical University, Hoang Van Luong ,   Biomedical & Pharmaceutical Applied Research Centre, Vietnam Military Medical University, Nghiem Duc Thuan ,   ENT Department, 103 Hospital, Vietnam Military Medical University
Published: May 2018

In Vietnam, nasopharyngeal carcinoma (NPC) is the eighth most common cause of death from cancer. Cell-free Epstein Barr virus DNA (cf-EBV DNA) was reported to be present in almost all NPC patients. However, currently available assays in Vietnam can detect cf-EBV DNA in only 67.6% of NPC patients, thus leaving 32.4% of cancer cases undetected. Therefore, in this study, we aim to develop a highly sensitive quantitative PCR (qPCR) assay that measures the load of cf-EBV DNA for the purpose of early detection of NPC, and then evaluate the sensitivity and the specificity of the developed qPCR assay on the clinical samples. The major methods used in this study include primer/TaqMan probe design, cf-DNA extraction, optimization of qPCR assay and statistical analysis. Using an international standard panel from the Chinese University of HongKong, the linear range of developed qPCR assay is from 50-150,000 copies/ml (R2 = 0.99613) and the detection limit has been shown to be 25 copies/ml. The developed assay could detect cf-EBV DNA with a sensitivity of 96.9% (31/32 NPC patients) and cf-EBV DNA has not been detected in 103 out of 105 healthy controls, which corresponds to a specificity of 98%. Consequently, the performance of the optimal assay has achieved remarkably high sensitivity and specificity. Moreover, the detection limit of our optimal qPCR assay is 25 copies/ml of plasma, which is at least ten times better than other assays tested in recent studies in Vietnam. This developed qPCR assay will also form the basis for further studies in Vietnam and will open many new applications in management of NPC.